CHARLES SCHWAB INVESTMENT MANAGEMENT INC - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$20,239,247
-21.0%
981,059
+13.1%
0.01%
-14.3%
Q2 2023$25,603,791
+32.9%
867,631
+3.7%
0.01%
+16.7%
Q1 2023$19,268,997
-17.2%
836,328
-0.0%
0.01%
-14.3%
Q4 2022$23,267,876
+3.7%
836,673
+14.5%
0.01%
-12.5%
Q3 2022$22,431,000
+4.2%
730,880
-0.1%
0.01%
+14.3%
Q2 2022$21,530,000
-5.0%
731,522
+3.9%
0.01%0.0%
Q1 2022$22,656,000
-29.2%
704,251
-1.8%
0.01%
-22.2%
Q4 2021$31,987,000
-9.9%
717,190
+1.9%
0.01%
-25.0%
Q3 2021$35,505,000
-29.3%
703,752
+9.9%
0.01%
-29.4%
Q2 2021$50,220,000
+55.5%
640,234
+13.2%
0.02%
+41.7%
Q1 2021$32,291,000
-21.8%
565,516
+14.7%
0.01%
-25.0%
Q4 2020$41,311,000
+137.0%
493,198
+1.4%
0.02%
+100.0%
Q3 2020$17,430,000
+53.0%
486,440
+3.2%
0.01%
+33.3%
Q2 2020$11,395,000
+55.4%
471,246
+12.6%
0.01%
+50.0%
Q1 2020$7,331,000
+12.4%
418,672
+11.8%
0.00%0.0%
Q4 2019$6,524,000
+15.9%
374,478
+2.0%
0.00%
+33.3%
Q3 2019$5,627,000
-23.2%
367,275
+4.0%
0.00%
-25.0%
Q2 2019$7,331,000
-6.8%
353,122
+4.3%
0.00%
-20.0%
Q1 2019$7,864,000
+18.1%
338,647
+5.1%
0.01%0.0%
Q4 2018$6,658,000
-5.7%
322,264
-0.8%
0.01%0.0%
Q3 2018$7,063,000
+482.3%
324,841
+308.5%
0.01%
+400.0%
Q2 2018$1,213,000
-7.0%
79,529
+20.1%
0.00%0.0%
Q1 2018$1,304,00066,2060.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Crestline Management, LP 7,705,039$343,645,00025.68%
Casdin Capital, LLC 1,500,000$66,900,0001.89%
Flagship Pioneering Inc. 2,619,968$116,851,0001.81%
SECTORAL ASSET MANAGEMENT INC 189,600$8,456,0001.27%
Integral Health Asset Management, LLC 100,000$4,460,0001.23%
Temasek Holdings (Private) Ltd 5,369,487$239,479,0000.86%
Goldstream Capital Management Ltd 78,418$3,497,0000.86%
Yiheng Capital Management, L.P. 335,184$14,949,0000.76%
GILDER GAGNON HOWE & CO LLC 2,900,114$129,345,0000.74%
Artal Group S.A. 600,000$26,760,0000.73%
View complete list of DENALI THERAPEUTICS INC shareholders